The first coronavirus vaccine has now been deemed "safe for humans" in a breakthrough study. Researchers at Beijing Institute of Biotechnology in Beijing, China, who carried out the study, say the vaccine produces a rapid immune response to the deadly disease.
The trial was carried out in 109 healthy adults between ages 18 and 60 and demonstrated promising results after 28 days— with the final results due to be evaluated in six months.
New research published in medical journal The Lancet hails the finding as "an important milestone". "The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for